Connect with us

Health

Dr. Reddy’s signs licensing deal with Pharmazz to market Centhaquine (Lyfaquin) in India

Published

on

Dr Reddy’s inks license agreement with Pharmazz to commercialise Centhaquine (Lyfaquin) in India, ET HealthWorld

Dr Reddy’s Laboratories Ltd has recently forged a license agreement with Pharmazz, Inc to leverage and distribute Centhaquine, an innovative drug used for the treatment of hypovolemic shock, in India. This groundbreaking agreement grants Dr Reddy’s exclusive rights to market and distribute the drug in the country, under the brand name Lyfaquin.

According to the Chief Executive Officer of Branded Markets at Dr Reddy’s, MV Ramana, this partnership with Pharmazz represents a significant milestone in bringing novel molecules to India to address unmet patient needs. Clinical studies have shown promising outcomes for Lyfaquin, positioning it as a potential game-changer in the management of hypovolemic shock.

Hypovolemic shock is a critical and often fatal condition resulting from severe loss of blood or fluids due to various factors like traumatic hemorrhage or post-surgical bleeding. With high mortality rates in India due to these conditions, the introduction of a novel resuscitative agent like Centhaquine holds immense promise in improving the standard of care for patients.

The CEO and Chairman of Pharmazz, Dr Prof Anil Gulati, highlighted the significance of partnering with Dr Reddy’s, a leading global pharmaceutical company, to bring Centhaquine to the Indian market. Recognizing India’s growing capabilities in research and development within the pharmaceutical sector, this collaboration aims to address the pressing medical needs of patients with hypovolemic shock.

Click to comment

You must be logged in to post a comment Login

Leave a Reply

Trending